Clinical Trials Browser

dacomitinib × 90 days × Clear all

NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Lung Neoplasms

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung